Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. by Jensen, P. B. et al.
Br. J. Cancer (1993), 67, 311 320
Ltd., 1993
Differential cytotoxicity of 19 anticancer agents in wild type and
etoposide resistant small cell lung cancer cell lines
P.B. Jensen', I.J. Christensen2, M. Sehested3, H.H. Hansen' & L. Vindel0v4
'Department ofOncology, The Finsen Institute/Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark; 2The Finsen
Laboratory, Rigshospitalet, DK-2100 Copenhagen; 3Department ofPathology, Sundby Hospital, DK-2300 Copenhagen;
4Department ofHematology, Rigshospitalet, DK-2100 Copenhagen.
Summary A panel of six 'wild type' and three VP-16 resistant small cell lung cancer (SCLC) cell lines is used
to evaluate to what extent in vitro sensitivity testing using a clonogenic assay can contribute to combine
cytotoxic drugs to regimens with improved efficacy against SCLC. The resistant lines include (a) H69/DAU4,
which is classical multidrug resistant (MDR) with a P-glycoprotein efflux pump (b) NYH/VM, which exhibits
an altered topoisomerase II (topo II) activity and (c) H69/VP, which is cross-resistant to vincristine, exhibits a
reduced drug accumulation as H69/DAU4 but is without P-glycoprotein. 19 anticancer agents were compared
in the panel. The MDR lines demonstrated, as expected, cross-resistance to all topo II drugs, but also different
patterns of collateral sensitivity to BCNU, cisplatin, ara-C, hydroxyurea, and to the topo I inhibitor
camptothecin.
The complete panel of nine cell lines clearly demonstrated diverse sensitivity patterns to drugs with different
modes of action. Correlation analysis showed high correlation coefficients (CC) among drug analogues (e.g.
VP-16/VM-26 0.99, vincristine/vindesine 0.89), and between drugs with similar mechanisms of action (e.g.
BCNU/Cisplatin 0.89, VP-16/Doxorubicin 0.92), whereas different drug classes demonstrated low or even
negative CC (e.g. BCNU/VP-16 -0.21). When the CC of the 19 drug patterns to VP-16 were plotted against
the CC to BCNU, clustering was observed between drugs acting on microtubules, on topo II, alkylating
agents, and antimetabolites. In this plot, camptothecin and ara-C patterns were promising by virtue of their
lack of cross-resistance to alkylating agents and topo II drugs. Thus, the differential cytotoxicity patterns on
this panel of cells can (1) give information about drug mechanism of action, (2) enable the selection and
combination of non-cross-resistant drugs, and (3) show where new drugs 'fit in' among established agents.
A panel of cell lines established from patients with small cell
lung cancer (SCLC) is used to evaluate to what extent in vitro
sensitivity testing can contribute to the selection and com-
bination of cytotoxic drugs to regimens with improved
efficacy. SCLC is one of the solid tumours most responsive to
cytotoxic drugs. More than ten established anticancer agents
are active against SCLC and first-line standard treatment
generally consists of combinations of some or all of these
drugs. Although these agents are effective in the initial treat-
ment of SCLC most of the patients relapse with a drug
resistant tumour (Hansen, 1992). This knowledge suggests
that we do not need new drugs with effect on the sensitive
cells, but drugs active on the resistant cells at relapse. The
epipodophyllotoxin VP-16 is one of the most effective drugs
when used as a single agent (Bork et al., 1991), and it is the
most frequently used drug in SCLC protocols (Kristjansen &
Hirsch, 1989). Thus, VP-16 will undoubtedly be widely used
in future protocols and mechanisms of resistance to this
important drug are therefore of special interest. Experimental
resistance to VP-16 always seems to include multidrug resis-
tance (MDR) with cross-resistance to other chemically
unrelated drugs (Ferguson et al., 1988; Long et al., 1991;
Sehested et al., 1992). Two well defined mechanisms of MDR
have been identified:
The first is reduction of the intracellular drug accumula-
tion (Dan0, 1973; Skovsgaard, 1978) due to P-glycoprotein in
the plasma membrane, also called classical MDR (reviewed
in (Endicott & Ling, 1989)). The second mechanism is altered
or reduced topoisomerase II activity reducing the target sen-
sitivity to most anthracyclines and epipodophyllotoxins (at-
MDR) (Danks et al., 1988). In SCLC both classical P-glyco-
protein MDR lines (Reeve et al., 1989; Minato et al., 1990;
Jensen et al., 1989b; de Vries, E.G.E. et al., 1989) and
at-MDR (de Jong et al., 1990; Jensen et al., 1991b) cells have
been described. In addition to these well defined mechanisms
of MDR, there are reports describing VP-16 and vincristine
cross-resistance in MDR SCLC cells without P-glycoprotein.
This was found in the MDR H69AT cell line by Cole et al.
(1991). Drug accumulation was apparently not reduced in
H69AT, whereas a reduction in drug accumulation was de-
scribed by Versantvoort et al. (1992) in their MDR cell line
GLC4. H69/VP developed in our laboratory belongs to this
last phenotype as it is P-glycoprotein negative, it is resistant
to VP-16 and vincristine (Jensen et al., 1992) and, as shown
in the present report, it exhibits a reduced drug accumula-
tion. Similar data have been obtained in NSCLC cell lines
and alternative drug efflux proteins or alternative mechan-
isms of MDR have been suggested (Cole, 1992; Coley et al.,
1991; Versantvoort et al., 1992). Such alternative mechanisms
of MDR may be of particular importance in lung cancer as
P-glycoprotein appears to be relatively seldom overexpressed
in lung cancer biopsies (Nooter & Herweijer, 1991).
In the clinic, drug-resistance is not confined to VP-16 and
the other MDR drugs and an ideal cell line panel with
relevant differential sensitivity patterns should probably in-
clude cell lines with resistance to all clinically important drug
types (e.g. also to alkylating agents). In our attempts to select
and develop such a panel we here report our results in a cell
line panel with VP-16 resistant lines included. In the present
investigations we evaluated the sensitivity patterns to 19
different anticancer agents on six wild type SCLC cell lines
and on the three MDR cell lines H69/DAU4, NYH/VM, and
H69/VP representing classical P-glycoprotein MDR, altered
topoisomerase II MDR, and a less defined MDR mechanism
exhibiting a reduced drug accumulation, respectively.
Materials and methods
Drugs
[3H] Daunorubicin (3.1 Ci/mmol) was obtained from DuPont
NEN. Melphalan (MEL) [Wellcome] was dissolved in hydro-
chloric acid with ethanol and further diluted in propylene-
glycol phosphate buffer, m-AMSA (MAM) [Parke-Davis]
was delivered in N,N-dimetylacetamid solution and further
diluted in acid lactose, and Ara-C (ARAC) (cytosine arab-
inoside) [Upjohn] was dissolved in benzyl alcohol, all the
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solvents used were dispensed by the producers. Doxorubicin
(DOX) [Farmitalia Carlo Erba], aclarubicin (ACLA) and
bleomycin (BLEO) [Lundbeck], hydroxyurea (HYD) [kindly
supplied by Bristol-Myers Squibb], 4'-deoxy-4'-iododoxorubi-
cin (IOD) (lododoxorubicin) [kindly supplied from Farmitalia
Carlo Erba], mitomycin C (MTC) [Kyowa], and vincristine
[Lilly] (VCR) were dissolved in sterile water. Vindesine
(VDS) [Lilly] was dissolved in isotonic sodium chloride.
Camptothecin (CAM) [Sigma] was dissolved in DMSO.
BCNU [Bristol-Myers Squibb] was dissolved in 10% v/v
ethanol in sterile water. Mitoxantrone (MIT) [Lederle], VP-
16 (etoposide) [Bristol-Myers Squibb], VM-26 (teniposide)
[Bristol-Myers Squibb], methotrexate (MTX) [Lederle], 5-
fluorouracil (SFU) [Roche] and cisplatin (CIS) [Bristol-Myers
Squibb] were in solution for infusion. The drugs were diluted
with tissue culture medium to 300 x final concentrations,
partitioned into multiple aliquots, frozen on ethanol-dry ice,
and stored at -80°C. Just prior to culture application the
contents of the frozen vials were thawed and mixed. The
cytotoxic stability of the frozen drugs stored at -80°C for
30-40 days was checked by comparing with freshly diluted
drug in a clonogenic assay. All drugs were checked in this
setting. Our major concern was the stability of the alkylating
agents. However, we observed no change in the cytotoxicity
of any of the drugs employed in this study. This stability of
the alkylating agents and of cisplatin agrees with previous
data published by Franco et al. (1984). To our surprise,
however, vinblastine was found to be unstable and was
therefore not included in the study.
Cell lines
The human SCLC cell lines used were, NCI-H69 (Carney et
al., 1985), NCI-N592 (Carney et al., 1985), OC-NYH (de Leij
et al., 1985), OC-TOL (de Leij et al., 1985), GLC-16 (Berend-
sen et al., 1988), and SCLC 86-Ml (Bepler et al., 1987). the
multidrug resistant (MDR) SCLC cell lines used were NCI-
H69/DAU4, NCI-H69/VP, and OC-NYH/VM selected for
resistance to daunorubicin, VP-16, and VM-26 respectively.
NCI-H69/DAU4 is a classical MDR cell line with P-
glycoprotein in the cell membrane (Jensen et al., 1989b),
OC-NYH/VM is resistant due to altered topoisomerase II
activity (Jensen et al., 1991b), and NCI-H69/VP is resistant
to vincristine as NCI-H69/DAU4, but is without P-glyco-
protein expression and the mechanism(s) responsible for
resistance in this line is still under investigation (Jensen et al.,
1992). Resistant cell lines were grown in vitro without drug
for a minimum of 5 days before testing. All cell lines were
maintained at 37°C in RPMI 1640 with 10% foetal calf
serum in a humidified atmosphere with 7.5% CO2. At regular
intervals the panel ofcell lines was re-established from frozen
sub-cultures to reduce or avoid sensitivity drifting. The cell
lines were free of mycoplasm contamination DNA content
(Vindel0v & Christensen, 1990), plating efficiency, relation to
chemotherapy, and growth behaviour in vitro of the cell lines
used are described in Table I. Also, Table I shows the
relative resistance of H69/DAU4, H69/VP, and NYH/VM to
doxorubicin (DOX), vincristine (VCR) and VP-16.
Determination of3H-daunorubicin accumulation
This was performed as described by Skovsgaard (1978) with
the modification that the SCLC cells in single cell suspen-
sions were incubated for 15 min with DNase I (0.025% w/v)
(Sigma) before being exposed to daunorubicin (Versantvoort
et al., 1992). This enzyme effectively dissolves the DNA in
nuclei from dead cells whereby the background binding was
significantly reduced (data not shown). Thereafter, single cell
suspensions of 2.5 x 106 viable cells ml-' in 2 ml (5 x 106
cells) were incubated with 3;LM [3H] daunorubicin for 60 min
in standard phosphate buffer (57.0 mm NaCl, 5.0 mm KCI,
1.3 mM MgSO4, 51.0mM Na2HPO4, 9.0mM NaH2PO4, pH
7.45) to which 5% (v/v) foetal calf serum was added. Incuba-
tions were performed with 10 mM glucose added, with 10 mM
sodium azide (NaN3) without glucose, with 10 mM sodium
azide and 10 mM glucose, or with 10 mM glucose and StM
verapamil. The cells were then spun down at 150g for 5 min
and washed twice with 10 ml of ice-cold PBS. The cell pellets
were solubilised in 0.8 ml 0.5 N KOH at 70°C for 1 h and
analysed for 3H in a Packard scintillation spectrometer
(Skovsgaard, 1978).
Clonogenic assay
We have previously demonstrated that the comparison of
effects of different drugs in a cell line is more reliable when
the drugs are compared in simultaneous experiments on the
same batch of cells (Jensen et al., 1989a). In our attempts to
rationalize 'in vitro phase II trials in SCLC' the task was
therefore to obtain more dose-response curves on one batch
ofcells. Since manual colony counting would be prohibitively
laborious, we developed an automatic colony counter consis-
ting of a videocamera built around a SB1024 image process-
ing board (Bio-Rad Scan-Beam, Hadsund, Denmark) equip-
ped with a motor steering for counting of 18 dishes. This
enabled the automatic counting of colonies in 200 Petri
dishes a day, with minimal expenditure of labour. In the
experiments, single-cell suspensions (1-4 x 104 cells ml-') in
RPMI 1640 supplemented with 10% foetal calf serum were
plated in soft agar on a feeder layer containing sheep red
blood cells (Roed et al., 1987) in 35 mm petri dishes with the
desired drug concentrations (continuous incubation). The
number of cells were adjusted to obtain 2000-3000 colonies
in the control dishes. In each experiment all 19 drugs (three
concentrations ofeach, all plated in triplicate) and six control
triplicates were tested on the same batch of cells. Solvent
concentrations never exceeded 1% and had no influence on
the plating efficiency. Plating was effectuated within one hour
as the intraexperimental variation in plating efficiency of the
controls exceeded 10% in more prolonged experiments. After
14-21 days the colonies were counted on the image analysis
system. Colonies larger than 5011M in diameter were regarded
Table I DNA content, plating efficiency, relation to chemotherapy, and growth
behavior in vitro and relative resistance of the cell lines used
Prior Growth RR
Cell line DI %PE therapy behaviour DOX VCR VP-16
NCI-H69 0.90 12 Yes S
H69/DAU4 0.87 12 S 5.1 5.1 2.3
H69/VP 0.82 13 S 6.3 7.9 17
OC-NYH 1.39 27 No Mon
NYH/VM 1.29 30 Mon 2.9 0.9 12
NCI-N592 1.48 30 Yes S
OC-TOL 1.40 22 No S
GLC-16 1.80 17 Yes S
SCCL 86M1 1.45 15 No S
DI DNA index; PE plating efficiency at approximately 3000 colonies; S (growth in
suspension) Mon (growth as monolayer); RR relative resistance i.e. the ratio of the
LD50 value for the resistant over that for the wild-type parent line, data from Jensen
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as positive. The colony counter was interfaced with an IBM
PS-2 60 computer and data was stored and analysed through
use of SAS software. The dose reducing the number of
colonies to 50% of control (LD50) was determined from
three drug concentration points in linear regression analysis
on logarithmically transformed response-data (Jensen et al.,
1989a). The drug concentrations chosen approximated to
LD1O, LD50, and LD90 obtained on cell line OC-NYH from
dose-response curves in previous experiments and were as
follows (gM): BCNU (2.3; 7.0; 14), 5FU (0.8; 1.2; 2.0),
ACLA (0.0037; 0.012; 0.025), DOX (0.018; 0.037; 0.055),
MEL (0.033; 0.1; 1), ARAC (0.025; 0.075; 0.15), BLEO
(0.007; 0.07; 0.35), CAM (0.0006; 0.0022; 0.0036), CIS (0.33;
1.4; 3.3), HYD (39; 79; 158), IOD (0.001; 0.005; 0.010),
MAMSA (0.01; 0.05; 0.1), MTX (0.02; 0.06; 0.11), MITO
(0.007; 0.014; 0.045), MTC (0.009; 0.015; 0.021), VCR
(0.0003; 0.001; 0.002), VDS (0.0005; 0.001; 0.002), VM26
(0.01; 0.02; 0.05), and VP16 (0.075; 0.125; 0.3). When the
calculated LD50 values were above 3 x the highest tested
concentration, the LD50 was assigned this value (i.e.
3 x LD90 on OC-NYH). Such 'horizontal' dose-response
curves were only observed with some of the 'MDR' drugs in
the resistant lines and accordingly their precise relative resis-
tance is not defined. The relative resistance obtained in
previous experiments with properly adjusted doses are shown
in Table I. Patterns in sensitivity were studied by correlation
analysis using rank orders of sensitivity with all possible
pairings of the 19 agents. LD50 values from two experiments
on each cell line were included in the analysis. Computations
utilised correlation coefficients calculated as Spearman rank
order correlations.
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Results
Sensitivity pattern in three different MDR cell lines
The cytotoxicity of the 19 anticancer agents was determined
in a clonogenic assay as described in Materials and methods.
The relative sensitivity to the 19 drugs in the 'wild type' cell
line NCI-H69 compared to NCI-H69/DAU4 is shown in
Figure la. In Figure lb NCI-H69 is compared to NCI-H69/
VP, and in Figure Ic the 'wild type' cell line OC-NYH is
compared to OC-NYH/VM. The interexperimental variation
on NCI-H69 is large (the coefficient of variation CV > 50%)
with MTX, 5-FU and bleomycin whereas CV <50% to the
rest of the drugs and most often CV<25%. Both resistant
sublines of H69 exhibit cross-resistance to the vinca alkaloids
VCR and VDS, to the anthracyclines doxorubicin (DOX)
and aclarubicin (ACLA), the anthracenidone mitoxantrone
(MIT), and to the 'classical' topoisomerase II targeting drugs
VP-16, VM-26 and m-AMSA (MAM). Interestingly NCI-
H69/VP appears sensitive to iododoxorubicin (IOD). Both
resistant sublines of H69 exhibit collateral sensitivity to
BCNU and Ara-C. Although not statistically significant both
lines also seem collaterally sensitive to cisplatin (CIS), camp-
tothecin (CAM), and hydroxyurea (HYD). In accordance to
our previous data (Jensen et al., 1989) the cell line NCI-H69
is four fold less sensitive to DOX than OC-NYH (LD50
0.091 and 0.023,.M respectively). As the drug concentrations
used were adjusted to OC-NYH sensitivity (please see
materials and methods) this means that the estimated cross-
resistance to DOX on H69/DAU4 is limited as compared to
the data in Table I.
In contrast to the MDR sublines of H69, there is no
cross-resistance to vinca alkaloids or to the anthracycline
aclarubicin (ACLA) in the at-MDR cell line OC-NYH/VM.
Compared to OC-NYH, the at-MDR cell line shows cross-
resistance to doxorubicin, iododoxorubicin, mitoxantrone, m-
AMSA and VP-16, and OC-NYH/VM also exhibits collateral
sensitivity to hydroxyurea and Ara-C. There is no change in
the sensitivity to camptothecin in this cell line. In Table II is
summarised the LD50 values used in the computations of the
relative sensitivities depicted in Figure 1. The median
coefficient of variation (CV) for the uncertainty in the LD50
computations was 9% and the median CV for the repeated
experiments was 30% (OC-NYH).
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Figure 1 The relative sensitivity to 19 anticancer agents in the
multidrug resistant cell lines a, NCI-H69/DAU4 and b, NCI-
H69/VP compared to the parental line NCI-H69 and in c, OC-
NYH/VM compared to the parental line OC-NYH. In the figures
are plotted the LD50 values obtained in three independent
experiments on the parental lines (0) and two experiments on
each of the resistant lines (*).
Daunorubicin accumulation in the three different MDR cell
lines
We have previously shown that NCI-H69/DAU4 expresses
P-glycoprotein (Jensen et al., 1989b), whereas the protein is
not detectable in the resistant sublines NCI-H69/VP and
OC-NYH/VM (Jensen et al., 1992). The cell line OC-NYH/
VM has the characteristics of an at-MDR phenotype (Danks
et al., 1988), whereas NCI-H69/VP is cross-resistant to vinc-
ristine and the resistance mechanism(s) in this cell line is still
unresolved. To further characterise the different resistant sub-
lines of NCI-H69 and OC-NYH, the accumulation of [3H]
daunorubicin was determined. Daunorubicin is a well des-
cribed P-glycoprotein substrate and as seen in Table III there
is a reduced daunorubicin accumulation in H69/DAU4 as
compared to the H69 'wild type'. When the H69/DAU4 cells
are incubated without glucose and in the presence of azide,
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Table II Mean LD50 values to 19 anticancer agents from three independent experiments
in NCI-H69 and OC-NYH, and from two independent experiments in the MDR sublines
H69/DAU4, H69/VP, and NYH/VM
Cell-Line
Drug NCI-H69 H69/DAU4 H69/VP OC-NYH NYH/VM
5FU giM 3.6 (2.4) 2.5 (1.2) 1.6 (0.06) 2.2 (1.7) 0.89 (0.14)
ACLA nM 12 (1.8) 45 (4.5) 17 8.2 (2.5) 7.3 (0.2)
DOX nM 91 (15) 134 (44) 166 (*) 23 (6) 134 (44)
MEL nM 621 (165) 846 (173) 407 (112) 431 (196) 519 (39)
ARAC nM 149 (33) 44 (16) 85 (15) 55 (5.6) 34 (5.7)
BCNU nM 4.2 (0.9) 2.3 (0.2) 2.5 8.6 (5) 4.9 (0.6)
BLEO gM 42 (31) 28 (11) 35 (20) 80 (50) 35 (0)
CAM nM 3.7 (0.5) 2.5 (0.5) 2.3 (1.5) 1.6 (0.4) 1.5 (0.2)
CIS nM 619 (160) 443 (13) 417 (72) 726 (185) 709 (36)
HYD giM 299 (65) 192 (20) 119 (1) 83 (3) 58 (7)
IOD nM 8.3 (1.5) 19 (2.4) 4.8 (2.6) 2.4 (1) 4.7 (1)
mAMSA nM 125 (29) 300 (*) 230 (99) 80 (31) 300 (*)
MTX nM 179 (144) 330 (*) 269 (86) 28 (12) 20 (1)
MIT nM 42 (2.7) 127 (12) 64 (2) 10 (3) 27 (2)
MTC nM 42 (15) 58 (2) 28 (7) 19 (7) 10 (3)
VCR nM 1.2 (0.2) 6.0 (*) 4.5 (0.9) 0.8 (0.3) 0.8 (0)
VDS nM 1.3 (0.2) 7.6 (2) 7.1 (2.4) 1.4 (0.3) 1.8 (0.8)
VM26 nM 57 (4) 150 (*) 150 (*) 14 (1.6) 150 (*)
VP16 nM 489 (94) 900 (*) 900 (*) 100 (17) 900 (*)
Numbers in parenthesis are standard deviations. Repeated LD50 values to ACLA and
BCNU are missing on cell line H69/VP.
*indicate that the LD50 value is 3 x higher than the highest dose tested.
Table III [3H] Daunorubicin accumulation in SCLC cells pretreated with DNase I
Accumulation in pmol daunorubicin/l06 cells
GLU SD AZID SD GLAZ SD GLV5 SD N
NCI-H69 544 (39) 699 (32) 551 (37) 514 (90) 6
H69/DAU4 170 (55) 488 (51) 197 (61) 333 (37) 5
H69/VP 324 (57) 719 (13) 496 (34) 588 (10) 5
OC-NYH 1078 (77) 1192 (113) 987 (108) 1035 (87) 5
NYH/VM 1077 (128) 1210 (169) 975 (110) 988 (112) 5
Accumulation in % of the parent wild type line
NCI-H69 100 (7) 128 (6) 101 (7) 94 (15)
H69/DAU4 31 (10) 90 (9) 36 (11) 61 (7)
H69/VP 60 (10) 132 (3) 92 (6) 108 (2)
OC-NYH 100 (7) 110 (10) 92 (10) 96 (8)
NYH/VM 100 (12) 112 (16) 90 (10) 92 (10)
SCLC cells were incubated for 60 min at 37°C with 3 JiM daunorubicin in: GLU, medium
containing 10 mm glucose; AZID, medium without glucose with 10 mM azid; GLAZ, medium
with 10 mm glucose and 10 mM azid; GLV5, medium with 10 mm glucose and 5JiM
verapamil. Hereafter the cells were washed at 4'C and drug accumulation was determined.
Numbers in parenthesis are standard deviations.
there is a 3-fold increase in daunorubicin accumulation
almost reaching a 'wild type' level. If energy production is
restored as seen by the effect of addition of glucose to the
azide incubations the drug accumulation is reduced. This
effect is similar to the results obtained by Dan0 (1973) on the
classic P-glycoprotein expressing MDR Ehrlich ascites
tumour cells. As expected, verapamil which is a modulator of
P-glycoprotein mediated resistance is also able to increase the
drug accumulation in H69/DAU4. A similar pattern is
observed in the P-glycoprotein negative H69/VP with a 2-fold
increase in drug content when the cells are incubated with
azide and a significant reduction by addition of glucose.
Thus, in both MDR sublines of H69 one explanation of the
resistance is a reduced drug accumulation. In contrast, there
is no difference in daunorubicin accumulation in OC-NYH
and OC-NYH/VM (Table III) although the latter is four fold
less sensitive to daunorubicin (Jensen et al., 1991b),
confirming that this cell line fits the at-MDR phenotype
(Danks et al., 1988).
Sensitivity patterns in six wild type and three MDR lines
The 19 drugs were tested on four additional 'wild type' cell
lines and Figure 2 shows the cytotoxicities of the drugs
against all six wild type cell lines and the three MDR SCLC
cell lines as determined by clonogenic assay. The cell lines are
sorted by increasing sensitivity to BCNU. Sensitivity varia-
tion across all lines to BCNU ranges from LD5O= 1.6.LM on
GLC-16 to LD5O= 14.0IM on cell line OC-TOL. The data
demonstrates that the variation in sensitivity to most drugs in
the 'wild type' lines is within a factor of 2-10. Sensitivity
patterns to VP-16 and BCNU are very different, whereas
patterns to VP-16 and VM-26 are identical and similar to the
pattern obtained with doxorubicin. Similarity in sensitivity
patterns are also obtained between vincristine and vindesine,
as well as to BCNU and cisplatin.
However, a more detailed visual comparison of patterns of
all possible drug pairings is obviously not feasible. We
therefore performed a correlation analysis using rank orders
of sensitivity with all possible pairings on the 19 agents.
From such an analysis, a high correlation coefficient for a
given pair of compounds is indicative of a similar pattern in
response in the set of cell lines. A numerically low coefficient
indicates that the two compounds are acting in different
ways, and a negative correlation coefficient suggests that two
drugs exhibit collateral sensitivity. Two separate experiments
from each of the nine SCLC cell lines (i.e. 18 LD50 values
for each drug) were used in the correlation analysis. Table
IV-A presents the correlation coefficients to all the possible
pairings. In accordance with the visual interpretation of the
data depicted in Figure 2, BCNU and cisplatin, VP-16 and
VM-26, as well as vincristine and vindesine have very highCLONOGENIC ASSAY IN SCLC CELL LINES 315
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Figure 2 Sensitivity patterns to 19 anticancer agents on nine SCLC cell lines. The results are depicted as the mean LD50 values
from at least two experiments and the cell lines are sorted by increasing sensitivity to BCNU. The three MDR lines are demarcated
with solid bars.
correlation coefficients (89%, 99%, and 89% respectively).
The sensitivity pattern to VP-16 is highly correlated to the
pattern to doxorubicin (92%), and the drug also exhibits
high correlation coefficients to the other topoisomerase TI
targeting agents mitoxantrone (81%) and m-AMSA (72%).
Table IV-A depicts a remarkable inverse correlation between
BCNU and MTX (-66%) as well as between bleomycin and
hydroxyurea (-61%). In addition, numerically smaller
inverse correlation coefficients are observed a number of
times. Thus the alkylating agents (BCNU and cisplatin), the
antimetabolites as well as bleomycin are all inversely cor-
related to the 'MDR' drugs, e.g. BCNU and bleomycin
correlation to mitoxantrone is -45% and -55% respec-
tively. Table IV-B shows correlation coefficients on the six
wild type lines alone, and thereby the consequence of includ-
ing the MDR lines in the cell line panel can be seen by
comparing table IV-A to IV-B. Although VP-16 and the
vinca alkaloids have different mechanisms of action, there is
a clear correlation between sensitivity patterns to these two
drug types not only in the full panel of nine SCLC lines
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Figure 3 Correlation coefficients between rank orders in sensitivity to 19 anticancer agents in nine SCLC cell lines and the
epipodophyllotoxin VP-16 are shown on the abscissa. The ordinate depicts correlation coefficients between the 19 agents and the
alkylating agent BCNU. Different drug types are demarcated in plot.
(Table IV-A) but also in the six 'wild types' (Table IV-B). In
contrast, both Ara-C and camptothecin demonstrate notable
reduced correlation coefficients to VP-16 when the MDR
lines are included. This reflects the collateral sensitivity
exhibited by these compounds in the MDR lines (Figure 1).
In order to visualise some of the data obtained on the full
cell line panel (Table IV-A), the correlations of the 19 drug-
patterns to the VP-16 sensitivity pattern were plotted against
the corresponding coefficients to BCNU (Figure 3). This plot
exhibits the remarkable feature of drug-type specific cluster-
ing. The topoisomerase II targeting drugs are clustered
together, as are the vinca alkaloids, and the lipophilic
anthracyclines (iododoxorubicin and aclarubicin). Although
more disparate, there also seem to be areas occupied by
alkylating agents and pyrimidine antimetabolites (ara-C and
5-FU). In addition, this plot demonstrates that drugs as
ara-C and camptothecin exhibit sensitivity patterns that differ
both from VP-16 and from the alkylating agents BCNU and
cisplatin. Thereby, the differential sensitivity patterns
obtained in the cell line panel enable the selection of non-
cross-resistant drugs.
Discussion
The present study demonstrates that the clonogenic assay
used on this panel of SCLC cell lines is capable ofdisplaying
both cell-determined and structure-determined differences in
the cytotoxicity of the drugs. As such the panel may provide
a useful adjunct to other tumour models in the selection of
non-cross-resistant anticancer agents and in elucidating
mechanisms of action of new drugs. That such patterns in
sensitivity may give clues to the mechanism of action was
recently described by Bai et al. (1991). Thus, in the National
Cancer Institute (NCI, Bethesda, USA) drug evaluation pro-
gram the two marine natural products halichondrin B and
homohalichondin B exhibited sensitivity patterns similar to
the antimitotic agent vincristine and it was subsequently
demonstrated that these potential new drugs are antimitotic
agents which interact with tubulin.
We chose to include experimentally developed resistant cell
lines in our panel. Such cell lines can be valuable when
displaying structurally determined differences in the cyto-
toxicity of drugs. We have previously shown that the anthra-
cycline aclarubicin (ACLA) does not stimulate topoisomerase
II mediated DNA breaks (Jensen et al., 1991a). This is in
contrast to other intercalating agents as doxorubicin and
mitoxantrone. The fact that there is cross-resistance to these
two drugs but not to ACLA in the at-MDR line OC-NYH/
VM (Figure 1c) strongly supports the idea that the cyto-
toxicity of ACLA, in contrast to doxorubicin and mitoxan-
trone, is independent of topoisomerase II activity (Jensen et
al., 1991b). While experimentally developed resistant cell lines
may elucidate drug mechanism of action it is debated wheth-
er such resistant cell lines reflect a relevant clinical
heterogeneity. An argument against the experimental lines is
that the high degree of resistance often seen in these lines is
far above what seems clinically relevant. As maximum
tolerated doses are often used, a 2-3 x decrease in sensitivity
is sufficient to explain clinical resistance. However, recent
clinical investigations demonstrate that MDR is not only a
laboratory investigation (Nooter & Herweijer, 1991). In
patients with acute myelocytic leukaemia there is a signifi-
cantly reduced survival of patients with overexpression of
mdrl mRNA in the leukaemia cells (Pirker et al., 1991). It is
still not settled whether the classical P-glycoprotein MDR
phenotype is involved in drug resistance in SCLC. P-glyco-
protein positive SCLC cell lines have been generated in the
laboratory by us and others (Reeve et al., 1989; Minato et
al., 1990; Jensen et al., 1989b), but the protein appears to be
rarely expressed in SCLC tumor biopsies (Nooter & Heerwei-
jer, 1991). Thus, other mechanisms of resistance may be
relevant in SCLC. The presence of alternative transport-
proteins have been suggested by Versantvoort et at. (1992)
and Cole et al. (1991) in their experimental MDR SCLC cell
lines, and our data on the P-glycoprotein negative H69/VP
cell line also suggest a MDR mechanism involving an active
drug efflux. Also alterations in topoisomerase II have been
described in experimentally resistant SCLC lines (de Jong et
al., 1990; Jensen et al., 1991b; Cole et al., 1991). The lack of
data on topoisomerase II activity in patient biopsies still only
enables speculations on its clinical relevance. Therefore, we
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chose to include different MDR phenotypes in our cell line
panel in an attempt to cover the whole (known) spectrum of
VP-16 resistance mechanisms.
The clonogenic assay is laborious and accordingly a
number of alternative, easier assys have been developed for
large-scale screening, e.g. MTT and protein assays (Car-
michael et al., 1988; Rubinstein et al., 1990). Instead ofusing
one of these methods we have rationalised the techniques in
the clonogenic assay. Cell handling and interexperimental
variation was reduced by using continuous drug exposure
(Jensen et al., 1989a,b), drugs were frozen in 'ready to use'
concentrations, and the time consuming colony counting was
automatized. Thereby, it became possible to obtain dose
response curves to 19 drugs simultaneously in a cell line.
Campling et al. (1991), Tasi et al. (1990), Smit et al. (1992),
and Carmichael et al. (1988) have recently published results
from MTT sensitivity testing in panels of SCLC cell lines. In
accordance with our findings, Campling et al. (1991) found
trends of collateral sensitivity to cisplatin, carboplatin, and
nitrogen mustard in a MDR subline of NCI-H69 selected for
resistance to doxorubicin. However, Tsai et al. (1990) did not
observe a differential cytotoxicity pattern to VP-16 and cisp-
latin in 27 'wild type' SCLC cell lines. In contrast to our
observations, cell lines resistant to the one drug was resistant
to the other and vice versa. More in agreement with our
observations, Carmichael et al. (1988) found lack of corre-
lation between VP-16 and cisplatin sensitivity in 15 'wild
type' SCLC cell lines. There are several explanations to this
variance in sensitivity patterns. Thus, different cell lines and
assays were employed. The MTT assay measures a combina-
tion of drug-induced cytotoxicity and inhibition of cell
growth (Campling et al., 1991), whereas the clonogenic assay
measures the loss of reproductive potential in single cells.
More importantly, however, the end point of the different
investigations differ. Campling et al. (1991), Smit et al.
(1992), and Tsai et al. (1990) correlated in vitro sensitivity
data with clinical outcome, whereas our focus is the com-
parison of drugs. Our attempt has been to select and develop
a cell line panel as a model of SCLC tumours reflecting
differential sensitivity patterns. Until now, we have concen-
trated our efforts on the various VP-16 resistant phenotypes.
In the clinic, drug resistance is not confined to VP-16 and an
ideal cell line panel should probably include cell lines with
resistance to all important drug types. Fortunately it appears
that our panel does include cell lines with an intrinsic resis-
tance towards alkylating agents e.g. OC-TOL and OC-NYH.
In addition, we are in the process of developing cell lines
with resistance to both VP-16 and cisplatin.
The value of a drug screening model is ultimately esta-
blished by its ability to identify combinations of drugs or
new compounds which are useful in clinical treatment. In this
context it is important that the model reflects experimental
and clinical experience. We feel that our model is supported
by the following findings:
(1) The clinical synergy between cisplatin and VP-16 in
SCLC (Porter et al., 1985) seems to be reflected in our
panel by the lack of cross-resistance or even collateral
sensitivity between cisplatin and VP-16 (e.g. in H69/
DAU4).
(2) Similarly, our data demonstrate a lack of cross-
resistance between topoisomerase II targeting agents e.g.
mitoxantrone and the antimetabolite ara-C. This com-
bination is widely used in the treatment of acute
myelocytic leukaemia.
(3) We find very high correlations between the two
epipodophyllotoxins VP-16 and VM-26 supporting the
clinical evidence that these drugs are similar (Bork et al.,
1991).
(4) It is debated whether topoisomerase II is the primary
target of doxorubicin and in this context it is interesting
that the two 'classic' topoisomerase II targeting agents
VP-16 and VM-26 also exhibit a very high correlation to
doxorubicin. Similar results on a large panel of 62 various
human tumor cell lines have recently been described from
the NCI drug discovery program by Wu et al. (1992), with
a correlation coefficient of 0.88 between VP-16 and dox-
orubicin.
Obviously, the treatment of SCLC with combinations of
topoisomerase II targeting drugs and alkylating agents is not
'enough' to cure the patients (Cantwell et al., 1988) and new
drugs with activity in the doubly resistant cell populations
are needed. The sensitivity correlations in Figure 3 and in
Table IV-A show that sensitivity patterns to ara-C and camp-
tothecin differ both from topoisomerase II targeting drugs
and from alkylating agents, wherefore ara-C and camp-
tothecin appear promising. While ara-C is not clinically
active in SCLC, its analogue gemcitabin has demonstrated
activity in non-small cell lung cancer (Anderson et al., 1991).
If gemcitabin exhibits a sensitivity pattern identical to ara-C,
our data suggests that it could be useful in combination with
alkylating agents and 'MDR drugs'. Drugs with effect on the
'new target' topoisomerase I also seem promising. There is
no cross-resistance to camptothecin in MDR, indeed, two of
our three MDR lines are collaterally sensitive to campto-
thecin. It is tempting to relate the inverse pattern of sen-
sitivity to the fact that topoisomerase II is able to replace
topoisomerase I in vitro (Liu et al., 1989; Yang et al., 1987).
Cells that are resistant to camptothecin appear to depend to
a greater extent than wild-type cells upon topoisomerase II
activity. This in turn can lead to collateral sensitivity to
topoisomerase II targeting agents (Sugimoto et al., 1990).
Such a hypersensitivity was recently described by Mattern et
al. (1991), and we found a similar sensitivity pattern in the
human RPM18402/k5 cell line with an altered topoisomerase
I (Kjeldsen et al., 1988; Kjeldsen et al., 1991). Thus, cells
resistant to topoisomerase I inhibitors are, in some cases at
least, hypersensitive to certain topoisomerase II inhibitors.
In conclusion the present study shows that it is feasible to
include 19 drugs in simultaneous experiments in a clonogenic
assay. The analysis of the differential cytotoxicity patterns in
the panel of cell lines makes it possible (i) to obtain inform-
ation about drug mechanism of action and enable combina-
tions of non-cross-resistant drugs and (ii) to show where new
drugs 'fit in' among established drugs. At present analogues
of ara-C and topoisomerase I active drugs appear to be
promising as they demonstrate low or negative correlation
coefficients both to topoisomerase II targeting agents and to
alkylating agents.
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